Janney Montgomery Scott LLC Purchases 39,969 Shares of OptimizeRx Corp. (NASDAQ:OPRX)

Janney Montgomery Scott LLC lifted its stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 47.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 124,751 shares of the company's stock after acquiring an additional 39,969 shares during the period. Janney Montgomery Scott LLC owned 0.67% of OptimizeRx worth $1,080,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. SBI Securities Co. Ltd. bought a new position in shares of OptimizeRx during the 4th quarter valued at about $25,000. GAMMA Investing LLC acquired a new stake in OptimizeRx during the first quarter valued at approximately $33,000. Wells Fargo & Company MN boosted its holdings in OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after buying an additional 2,797 shares in the last quarter. Graham Capital Management L.P. acquired a new position in OptimizeRx in the fourth quarter worth approximately $81,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of OptimizeRx by 504.6% in the fourth quarter. BNP Paribas Financial Markets now owns 22,308 shares of the company's stock valued at $108,000 after buying an additional 18,618 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on OPRX shares. JMP Securities lifted their price target on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research note on Tuesday, May 13th. Stifel Nicolaus boosted their target price on shares of OptimizeRx from $12.50 to $16.00 and gave the company a "buy" rating in a research note on Monday, June 9th. Wall Street Zen raised OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. B. Riley reissued a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, Citigroup restated an "outperform" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $10.81.

OptimizeRx Stock Up 3.3%

Shares of NASDAQ OPRX traded up $0.43 during mid-day trading on Thursday, reaching $13.55. 78,613 shares of the company traded hands, compared to its average volume of 300,274. The company's fifty day moving average is $11.99 and its two-hundred day moving average is $8.29. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.82 and a current ratio of 2.82. OptimizeRx Corp. has a fifty-two week low of $3.78 and a fifty-two week high of $15.71. The stock has a market cap of $250.68 million, a PE ratio of -16.13, a price-to-earnings-growth ratio of 4.53 and a beta of 1.34.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 0.29% and a negative net margin of 16.33%. The business had revenue of $21.93 million for the quarter, compared to analyst estimates of $18.69 million. On average, analysts expect that OptimizeRx Corp. will post -0.33 earnings per share for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.